Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience
2024 · Inflammatory Bowel Diseases · 20 citations
https://doi.org/10.1093/ibd/izae112
R
Ronen Stein
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
42
Papers
462
Citations
10
h-index
12
i10-index
Ronen Stein is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Immunodeficiency and Autoimmune Disorders. The author has an h-index of 10, co-authored 36 publications.
ORCID: 0000-0002-4494-2388Papers by this author
worksMaintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study
2025 · The Lancet. Gastroenterology & hepatology · 10 citations
https://doi.org/10.1016/s2468-1253(24)00319-4
Pediatric Gastrointestinal Tract Outcomes During the Postacute Phase of COVID-19
2025 · JAMA Network Open · 10 citations
https://doi.org/10.1001/jamanetworkopen.2024.58366
Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the <scp>VedoKids</scp> Prospective Multicentre Study
2025 · Alimentary Pharmacology & Therapeutics · 7 citations
https://doi.org/10.1111/apt.18484
623 MAINTENANACE VEDOLIZUMAB TREATMENT IN PEDIATRIC IBD: 54-WEEK FOLLOW-UP OF THE PROSPECTIVE MULTICENTER VEDOKIDS STUDY
2024 · Gastroenterology · 0 citations
https://doi.org/10.1016/s0016-5085(24)00820-5
Mo2038 EFFECTIVENESS AND SAFETY OF RISANKIZUMAB IN CHILDREN WITH CROHN'S DISEASE
2024 · Gastroenterology · 0 citations
https://doi.org/10.1016/s0016-5085(24)03230-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat